Molecular biology of prostate development and prostate cancer

Annals of Medicine

Volumn 30, Issue 4, 1998, Pages 357-368

  Sciavolino, Peter J ^a   Abate Shen, Cory ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Gene expression; Prostate cancer; Prostate development

Indexed keywords

CELL ADHESION MOLECULE; GROWTH FACTOR; TRANSCRIPTION FACTOR;

CARCINOGENESIS; DEVELOPMENT; GENE; HOMEOBOX; HUMAN; MALE; MOLECULAR BIOLOGY; ORGANOGENESIS; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTO ONCOGENE; REVIEW;

EID: 0031696988     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899809029935     Document Type: Review

References (136)

1. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocrine Rev 1987; 8: 338-62.
2. Cunha GR. Role of mesenchymal-epithelial interactions in normal and abnormal development of male urogenital glands. In: Riva, A, Testa Riva, F and Motta, PM, eds. Ultrastructure of Male Urogenital Glands: Prostate, Seminal Vesicle Urethral and Bulbourethral Glands. New York: Kluwer Academic Publishers; 1994: 15-34.
3. Coffey DS. Prostate cancer: an overview of an increasing dilemma. Cancer 1992; 71: 880-6.
4. Dong J-T, Issacs WB, Isaacs JT. Molecular advances in prostate cancer. Curr Opin Oncol 1997; 9: 101-7
5. Cunha GR. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 1994; 74: 1030-44.
6. Cunha GR. Age-dependent loss of sensitivity of female urogenital tract epithelia to androgenic conditions as a function of epithelial-stromal interaction. Endocrinology 1975; 95: 665-73.
7. Cunha GR, Fujii H, Neubauer BL, Shannon JM, Sawyer LM, Repese BA. Epithelial-mesenchymal interactions in prostatic development: I. Morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 1983; 96: 1662-70.
8. Hayward SW, Cunha GR, Dahiya R. Normal development and carcinogenesis of the prostate: a unifying hypothesis. Ann N Y Acad Sci 1996; 784: 50-62.
9. McNeal JE. Evolution of benign prostatic enlargement. Invest Urol 1978; 15: 340-5.
10. Chung LWK. Fibroblasts are critical determinants of prostate cancer growth and dissemination. Cancer Metastasis Rev 1991; 10: 263-74.
11. Gleave ME, Hseieh JT, Von Eschenbach AC, Chung LWK. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 1992; 147: 1151-9.
12. Hyytinen E-R, Thalmann GR, Zhau HE, et al. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer 1997; 75: 190-5.
13. Peehl DM. Oncogenes in prostate cancer: an update. Cancer 1993; 71: 1159-64.
14. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome wide search. Science 1996; 274: 1371-4.
15. Tamagnone L, Comoglio PM. Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. Cytokine Growth Factor Rev 1997; 8: 129-42.
16. Chung LWK, Li W, Gleave ME, et al. Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl 1992; 16H: 99-105.
17. Pisters LL, Troncoso P, Zhau HE, Li W, Von Eschenbach AC, Chung LWK. c-met protooncogene expression in benign and malignant human prostate tissues. J Urol 1995; 154: 293-8.
18. Vaux DL, Cory S, Adams JL. Bcl-2 gene promotes haemopoetic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2.
19. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6.
20. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the proto-oncogene bcl-2 in prostate cancer and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4.
21. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996; 2: 389-98.
22. Raffo AJ, Perlman H, Chen MW, Day ML, Streiman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-45.
23. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-95.
24. Beato M. Gene regulation by steroid hormones. Cell 1989; 56: 335-44.
25. Cooke PS, Young P, Cunha GR. Androgen receptor expression in developing male urogenital organs. Endocrinology 1991; 128: 2867-73.
26. Takeda H, Mizuno T, Lasnitski I. Autoradiographic studies of androgen binding sites in the rat urogenital sinus and postnatal prostate. J Endocrinol 1985; 104: 87-92.
27. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992; 89: 6319-23.
28. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46: 759-65.
29. Harris SE, Rong Z, Harris MA, Lubahn DD. Androgen receptor in human prostate carcinoma LNCaP/ADEP cells contain a mutation which alters the specificity of the steroid-dependent transcriptional activation region. Endocrinology 1990; 126 (Suppl): 93.
30. Veldschote J, Ris-Staplers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173: 534-40.
31. Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994; 54: 2861-4.
32. Cullig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541-50.
33. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-9.
34. Blackwood EM, Eisenman RN. Max: a helix-loop-helix-zipper protein that forms a sequence-specific DNA binding complex with myc. Science 1991; 251: 1211-7.
35. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes myc transcriptional activity. Cell 1993; 72: 211-22.
36. Zevros A, Gyuris J, Brent R. Mxi1, a protein that specifically interacts with max to bind myc-max recognition sites. Cell 1993; 72: 223-32.
37. DePinho R, Schreiber-Agus N, Alt FW. Myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 1991; 57: 1-46.
38. Buttyan R, Sawczuk IS, Benson MC, et al. Enhanced expression of the c-myc protooncogene in high grade human prostate cancers. Prostate 1987; 11: 327-37.
39. Netto GJ, Humphrey PA. Molecular biologic aspects of human prostatic carcinoma. Am J Clin Pathol 1994; 102 (Suppl 1): S57-64.
40. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997; 57: 524-31.
41. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV. Mutation of the MXI1 gene in prostate cancer. Nat Genet 1995; 9: 249-55.
42. Lane DP. p53, guardian of the genome. 1992; 358: 15-6.
43. Navone NM, Troncoso P, Pisters LL, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657-69.
44. Bookstein R, MacGrogan D, Hilsenbeck SG, et al. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53: 3369-73.
45. Effert PJ, McCoy RH, Walther PJ, et al. p53 gene alterations in human prostate carcinoma. J Urol 1993; 150: 257-61.
46. Visakorpi T, Kallioniemi OP, Heikkinen A, et al. Small subgroup of agressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84: 883-7.
47. MacGrogan D, Bookstein R. Tumor supressor genes in prostate cancer. Semin Cancer Biol 1997; 8: 11-19.
48. Davidson D. The function and evolution of Msx genes: pointers and paradoxes. Trends Genet 1995; 11: 405-11.
49. He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997; 43: 69-77.
50. Voeller HJ, Augustus M, Madlike V, Bova GS, Carter KC, Gelmann EP. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res 1997; 57: 4455-59.
51. Bieberich CJ, Fujita K, He WW, Jay G. Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem 1996; 271: 31779-82.
52. Sciavolino PJ, Abrams EW, Yang L, Austenberg LP, Shen MM, Abate-Shen C. Tissue specific expression of murine Nkx3.1 in the male urogenital system. Dev Dynamics 1997; 209: 127-38.
53. Oefelein M, Chin-Chance C, Bushman W. Expression of the homeotic gene Hox-d13 in the developing and adult mouse prostate. J Urol 1996; 155: 342-6.
54. Podlasek CA, Duboule D, Bushman W. Male accesory organ morphogenesis is altered by loss of function of Hoxd-13. Dev Dynamics 1997; 208: 454-65.
55. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell 1992; 68: 283.
56. Krumlauf R. Hox genes in vertebrate development. Cell 1994 78; 191-201.
57. Scott MP. Vertebrate homeobox gene nomenclature. Cell 1992; 71: 551-3.
58. Zeltser L, Desplan C, Heintz N. Hoxb-13: a new Hox gene in a distant region of the HOXB cluster maintains colinearity. Development 1996; 122: 2475-84.
59. Dolle P, Izpisua-Belmonte JC, Brown JM, Tickle C, Duboule D. Hox-4 genes and the morphogenesis of the mammalian genitalia. Genes Dev 1991; 5: 1767-76.
60. Dolle P, Izpisua-Belmonte JC, Boncinelli E, Duboule D. The Hox 4.8 gene is localized at the extreme 5′ extremity of the Hox-4 complex and is expressed in the most posterior parts of the body during development. Mech Dev 1991; 36: 3-13.
61. Gao AC, Isaacs JT. Expression of the homeobox gene-GBX-2 in human prostatic cancer cells. Prostate 1996; 29: 395-98.
62. Matsui T, Hirai M, Hirano M, Kurosawa Y. The HOX complex heighbored by the EVX gene, as well as two other homeobox-containing genes, the GBX-class and the EN-class, are located on the same chromosomes 2 and 7 in humans. FEBS Lett 1993; 336: 107-10.
63. Culig Z, Hobisch A, Cronauer MV, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996; 28: 392-405.
64. Gregory H, Willshire IR, Kavanagh JP, Blacklock NJ, Chowdury S, Richards RC. Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hyperplasia. Clin Sci 1986; 50: 359-63.
65. Hiramatsu M, Kashimata M, Minami N, Sato A, Murayama M. Androgenic regulation of epidermal growth factor in the mouse ventral prostate. Biochem Int 1988; 17: 311-7.
66. St Arnaud R, Poyet P, Walder P, Labrie F. Androgens regulate epidermal growth factor receptor levels in the rat ventral prostate. Mol Cell Endocrinol 1988; 56: 21-7.
67. Traish AM, Wotiz HH. Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 1987; 121: 1461-7.
68. Henttu P, Vihko P. Growth factor regulation of gene expression in the human prostate cancer cell line LNCaP. Cancer Res 1993; 53: 1051-8.
69. Connoly JM, Rose DP. Production of epidermal growth factor and transforming growth factor-α by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 1990; 16: 209-18.
70. Connoly JM, Rose DP. Secretion of epidermal growth factor and related polypeptides by the DU-145 human prostate cell line. Prostate 1989; 15: 177-86.
71. Fowler JE Jr, Lau JLT, Ghosh L, Mills SE, Mounzer A. Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol 1988; 139: 857-61.
72. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of human prostatic carcinoma cells: role of transforming growth factor-α. Cancer Res 1991; 51: 2780-85.
73. Wilding G, Valverius E, Knabbe C, Gelmann EP. Role of transforming growth factor alpha in human prostate cancer cell growth. Prostate 1989; 15: 1-12.
74. Harper ME, Goddard L, Glynne-Jones E, et al. An immunocytochemical analysis of TGF-α expression in benign and malignant prostatic tumors. Prostate 1993; 23: 9-23.
75. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC. Overexpression of TGF-α in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 1990; 61: 1121-35.
76. MacDonald A, Habib FK. Divergent responses to epidermal growth factor in hormone-sensitive and insensitive human prostate cancer cell lines. Br J Cancer 1992; 65: 177-82.
77. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Sporn MB, Roberts AB, eds. Handbook of Experimental Pharmacology. Heidelberg, Germany: Springer-Verlag; 1990: 419-72.
78. Massague J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6: 597-641.
79. Story MT, Hopp KA, Meier DA, Begun FP, Lawson RK. Influence of transforming growth factor β1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts. Prostate 1993; 23: 183-97.
80. Kyprianou N, Isaacs JT. Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989; 3: 1515-22.
81. Kyprianou N, Martikainen P, Davis L, English HF, Isaacs JT. Programmed cell death as a new target for prostate cancer therapy. In: Isaacs JT, ed. Prostate Cancer: Cell and Molecular Mechanisms in Diagnosis and Treatment. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1991: 265-78.
82. Kyprianou N, Isaacs JT. Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology 1988; 123: 2124-31.
83. Watts RG, Ware JL. Isolation and characterization of transforming growth factor beta response variants from human prostatic tumor cell lines. Prostate 1992; 21: 223-37.
84. Wilding G, Zugmeier G, Knabbe C, Flanders KC, Gelmann EP. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 1989; 62: 79-87.
85. Steiner MS, Barrack ER. Transforming growth factor β1 overproduction in prostate cancer: effects on growth in vitro and in vivo. Mol Endocrinol 1992; 6: 15-25.
86. Katz AE, Benson MC, Wise GJ, et al. Gene activity during the early phase of androgen-stimulated rat prostate regrowth. Cancer Res 1989; 49: 5889-94.
87. Story MT, Livingston B, Baeten L, et al. Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 1989; 15: 355-65.
88. Mori H, Maki M, Oishi K, et al. Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasia. Prostate 1990; 16: 71-80.
89. Begun FP, Story MT, Hopp KA, Shapiro E, Lawson RK. Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J Urol 1995; 153: 839-43.
90. McKeehan WL, Adams PS, Fast D. Different hormonal requirements for androgen independent growth of normal and tumor epithelial cells from rat prostate. In Vitro Cell Dev Biol 1987; 23: 147-52.
91. Nakamoto T, Chang C, Li A, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992; 52: 571-7.
92. Marchese C, Rubin J, Ron D, et al. Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: differentiation response distinguishes KGF from EGF family. J Cell Physiol 1990; 144: 326-32.
93. Alarid ET, Rubin JS, Young P, et al. Keratinocyte growth factor functions in epithelial induction during seminal vesicle development. Proc Natl Acad Sci U S A 1994; 91: 1074-8.
94. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial andromedin. Mol Endocrinol 1992; 6: 2123-8.
95. Kitsberg DI, Leder P. Keratinocyte growth factor induces mammary and prostatic hyperplasia in transgenic mice. Oncogene 1996; 13: 2507-15.
96. Dahiya R, Haughney PC, Chui R, Ho R, Deng G. Differential gene expression of transforming growth factors alpha and beta, epidermal growth factor, keratinocyte growth factor, and their receptors in fetal and adult human prostatic tissues and cancer cell lines. Urology 1996: 13: 963-70.
97. Payson RA, Wu J, Liu Y, Chiu I-M. The human FGF-8 gene localizes on chromosome 10q24 and is subjected to induction by androgen in breast cancer cells. Oncogene 1996: 13: 47-53.
98. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989; 10: 68-91.
99. Cohen P, Peehl DM. Insulin-like growth factors (IGFs), IGF receptors, and IGF binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1990; 73: 401-7.
100. Perkel VS, Mohan S, Baylink SJ, Linkhart TA. An inhibitory insulin-like growth factor binding protein (IN-IGFBP) from human prostate cell conditioned medium reveals and N-terminal sequence identity with bone-derived IN-IGFBP. J Clin Endocrinol Metab 1990; 71: 533-5.
101. Iwamura M, Sluss PM, Casamento JB, Cockett ATK. Insulin-like growth factor-I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993; 22: 243-52.
102. Pietrzowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of human prostate cancer cell lines by peptide analogs of insulin-like growth factor 1. Cancer Res 1993; 53: 1102-6.
103. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor -I and prostate cancer risk: a prospective study. Science 1997; 279: 563-6.
104. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 64: 5474-8.
105. Culig Z, Hobisch A, Radmayr C, et al. Regulation of androgen-receptor mediated gene transcription in the prostatic tumor cell line DU-145 by cyclic adenosine monophosphate, insulin-like growth factor-I, phorbol ester, and retinoic acid. Proc Am Assoc Cancer Res 1995; 36: 1618.
106. Hsieh JT, Lin SH. Androgen regulation of cell adhesion molecule gene expression in rat prostate during organ degeneration: C-CAM belongs to a class of androgen-repressed genes associated with enriched stem/amplifying cell population after prolonged castration. J Biol Chem 1994; 269: 3711-6.
107. Kleinerman D, Troncoso P, Brooks T, von Eschenbach AC, Lin SH, Hsieh JT. The expression of an epithelial cell adhesion molecule (C-CAM) in human prostate development and in prostate carcinoma: implication as a tumor supressor. Cancer Res 1995; 55: 1215-20.
108. Hsieh JT, Luo W, Song W, et al. Tumor supressive role of an androgen regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 1995; 55: 190-7.
109. Kleinerman D, Zhang W-W, Lin S-H, Van NT, von Eschenbach AC, Hsieh JT. Application of a tumor supressor (C-CAM1)-expressing recombinant adenovirus in androgen-idependent human prostate cancer therapy: a preclinical study. Cancer Res 1995; 55: 2831-6.
110. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-5.
111. Hinck L, Näthke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 1994; 125: 1327-40.
112. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989; 108: 2435-47.
113. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion supressor role. Cell 1991; 66: 107-19.
114. Bussemakers MJG, van Moorselaar RJA, Giroldi LA, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992; 52: 2916-22.
115. Giroldi LA, Schalken JA. Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 1993; 12: 29-37.
116. Umbas R, Isaacs WB, Bringuier PP, et.al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54: 3929-33.
117. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high grade prostate cancer. Cancer Res 1992; 52: 5104-9.
118. Richmond PJM, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant E-cadherin and α-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 1997; 57: 3189-93.
119. Underhill C. CD44: the hyaluron receptor. J Cell Sci 1992; 103: 293-8.
120. Gakunga P, Frost G, Shuster S, Cunha G, Farneby B, Stern R. Hyaluron is a prerequisite for ductal branching morphogenesis. Development 1997; 124: 3987-97.
121. Screaton GR, Bell MV, Bell JI, Jackson DG. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160-4.
122. Gunthert U, Stauder R, Mayer B, Terpe H, Finke L, Friedrichs K. Are CD44 variant isoforms involved in human tumor progression? Cancer Surv 1995; 24: 19-42.
123. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
124. Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991; 174: 859-66.
125. Salmi M, Virta GP, Sointu P, Grenman R, Kalimo H, Jalkanen S. Regulated expression of exon v6 containing isoforms in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 1993; 122: 431-42.
126. Tanabe KK, Stamenkovic I, Culter BS, Takahashi K. Restoration of CD44H expression in colon carcinoma reduces tumorigenicity. Ann Surg 1995; 222: 493-503.
127. Ichikawa Y, Dong J-T, Hawkins AI, et al. Localization of metastasis supressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 1992; 52: 3486-90.
128. Gao AC, Lou W, Dong J-T, Isaacs JT. CD44 is a metastasis supressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997; 57: 846-9.
129. Kallakury BVS, Yang F, Figge J, et al. Decreased levels of CD44 protein and mRNA in prostate carcinoma: correlation with tumor grade and ploidy. Cancer 1996; 78: 1461-9.
130. Isaacs JT, Isaacs WB, Feitz WFJ, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostate cancers. Prostate 1986; 9: 261-81.
131. Rinker-Schaeffer CW, Hawkins AL, Ru N, et al. Differential supression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 1994; 54: 6249-56.
132. Dong J-T, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis supressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268: 884-6.
133. Dong J-T, Suzuki H, Pin SS, et al. Down-regulation of KAI1 metastasis supressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996; 56: 4387-90.
134. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR. Thymosin β-15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nature Med 1996; 2: 1322-8.
135. Yu F-X, Lin SC, Morrison-Bogorad M, Yin HL. Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J Biol Chem 1993; 268: 502-9.
136. Pantaloni D, Carlier MF. How profilin promotes actin filament assembly in the presence of thymosin beta 4. Cell 1993; 75: 1007-14.